STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

NCT06880523 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

140

Enrollment

NETWORK

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: STRIDE (durvalumab + tremelimumab)
DRUG: Durvalumab
DRUG: Lenvatinib

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]
[object Object]